Bevacizumab 5 mg/kg

DRUG3 trials

Sponsors

Hoffmann-La Roche, Abramson Cancer Center at Penn Medicine, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Colorectal CancerMetastatic Breast CancerRectal Cancer Patients

Phase 2

DCE-MRI PET Bevacizumab Study in Rectal Cancer

WithdrawnNCT01426074

Abramson Cancer Center at Penn MedicineRectal Cancer Patients

Start: 2011-08-31End: 2014-06-11Updated: 2018-08-21

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

Cancer Institute and Hospital, Chinese Academy of Medical SciencesMetastatic Breast Cancer

Start: 2020-04-01End: 2023-12-31Target: 138Updated: 2022-02-25

Phase 3

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

CompletedNCT00069095

Hoffmann-La RocheColorectal Cancer

Start: 2003-07-31End: 2009-04-30Updated: 2016-10-06

Related Papers

Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial.

2024-07-0515 citations

An immunogenic cell death-related signature for prediction of prognosis and response to immunotherapy in breast cancer

Chinese Medical Journal2023-11-212 citations

Efficacy outcomes with bevacizumab added to chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2018-02-015 citations